1. Scrip
  2. >>R&D
  3. >>Clinical Trials

Flexion: The In-Licensing Advantage of Cheap Proof-of-Concept

 
• By Roger Longman

The founders of Lilly's radical Chorus experiment have left the mother ship to do the extraordinarily fast and inexpensive proof-of-concept development that have made Chorus one of the most interesting models in the industry. The two new entrepreneurs, backed by Versant, hope that their new company, Flexion, will be able to preferentially sign deals for the shelved molecules that a host of in-licensing start-ups have also been seeking.

In 2002, Eli Lilly & Co. began to experiment with a radically new process for clinical development: rapid proof-of-concept (POC). It was by no means the first such experiment in the industry, but Lilly has been the only company to stick with it, institutionalizing the ideas in its quasi-independent Chorus division (See "Lilly’s Chorus Experiment," IN VIVO, May 2007 Also see "Lilly's Chorus Experiment" - In Vivo, 1 May, 2007.).

Now Chorus’ two top executives are going out on their own, setting up a Chorus-style competitor called Flexion Therapeutics Inc.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Clinical Trials

Otsuka’s IgAN Data Top Some Vera Results, But To What End?

 
• By Joseph Haas

Otsuka bested Vera on Phase III immunoglobulin A nephropathy data for proteinuria, but analysts wonder if the difference is especially meaningful.

ASCO: Kite’s Glioblastoma CAR-T Highlights Solid Tumor Progress

 
• By Alaric DeArment

The company presented Phase I data for CART-EGFR-IL13Rα2, showing patient responses in the notoriously hard-to-treat and deadly brain cancer.

Santen Sees Potential In Myopia Market After Ryjunea Approval

 
• By Kevin Grogan

The low-dose atropine eye drop slowed the progression of pediatric myopia by 30%.

Will Pfizer Walk Away From Arvinas After PROTAC Disappointment?

 
• By Andrew McConaghie

Arvinas and Pfizer have just filed the potential first-in-class protein degrader vepdegestrant, but its diminished commercial prospects after mixed Phase III data mean Pfizer could exit.

More from R&D

Deal Build-Up Amid Early ‘Deep’ Response For IGI’s Trispecific In Myeloma

 
• By Anju Ghangurde

IGI CEO tells Scrip about the “very encouraging” feedback at ASCO to promising early data for the firm's first-in-class investigational trispecific antibody in multiple myeloma. Is a licensing deal in the offing?

Ascletis Plans China Submission After Positive Denifanstat Phase III Acne Results

 
• By Sushmita Panda

Once-daily oral FASN inhibitor denifanstat meets all endpoints in a Chinese Phase III trial for moderate-to-severe acne, paving the way for a regulatory submission in China.

New Regenxbio DMD Data Support Gene Therapy Accelerated Approval

 
• By Joseph Haas

Regenxbio reported functional and biomarker data from an ongoing study of RGX-202, which it hopes to file for approval in Duchenne muscular dystrophy in 2026.